Curaleaf Holdings CURLF
OTC CURLF
$9.83 +0.64 (+6.96%)
At close: Aug 19, 2026 · 3:59 PM UTC

Curaleaf Holdings (CURLF) Net Income towards Common Stockholders (2019 - 2026)

Curaleaf Holdings (CURLF) posted quarterly Net Income towards Common Stockholders of -$293000.0 for Q1 2026, up 97.13% year-over-year from -$148636.3 in Q1 2025, and up 98.13% quarter-over-quarter from -$15.7 million in Q4 2025.

Curaleaf Holdings (CURLF) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Curaleaf Holdings' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$293000.0 for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 97.13% year-over-year to -$293000.0; the TTM figure through Mar 2026 stood at -$21.1 million (changed 0.31% YoY), while the FY2025 annual figure was -$26.2 million, down 152.45% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$293000.0, up from -$15.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $21.4 million in Q1 2022, with the low at -$8.0 billion in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$7.9 million (2023), against an average of -$480.3 million.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders tumbled 9157.22% in 2023, then surged 106.25% in 2024.
  • Curaleaf Holdings' Net Income towards Common Stockholders stood at -$86.4 million in 2022, then sank by 9157.22% to -$8.0 billion in 2023, then surged by 99.86% to -$11.3 million in 2024, then tumbled by 38.46% to -$15.7 million in 2025, then soared by 98.13% to -$293000.0 in 2026.
  • Business Quant data shows CURLF's Net Income towards Common Stockholders at -$293000.0 in Q1 2026, -$15.7 million in Q4 2025, and -$2.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.81 Bn 42.84 Bn - -
2 Teva Pharmaceutical Industries 43.29 Bn 39.63 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.59 Bn 29.91 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.67 Bn 22.88 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.24 Bn 19.58 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.79 Bn 17.91 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.71 Bn 15.32 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.09 Bn 11.56 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.95 Bn - -
10 Curaleaf Holdings 2.51 Bn 2.42 Bn 169.91 Mn 12.52 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 31,000.00
Mar 31, 2026 -293,000.00
Dec 31, 2025 -15.66 Mn
Sep 30, 2025 -2.14 Mn
Jun 30, 2025 -3.00 Mn
Mar 31, 2025 -10.19 Mn
Dec 31, 2024 -11.31 Mn
Sep 30, 2024 1.62 Mn
Jun 30, 2024 -1.28 Mn
Mar 31, 2024 567,000.00
Dec 31, 2023 -8.00 Bn
Sep 30, 2023 -25.92 Mn
Jun 30, 2023 -7.90 Mn
Mar 31, 2023 -12.59 Mn
Dec 31, 2022 -86.37 Mn
Sep 30, 2022 -12.73 Mn
Jun 30, 2022 -4.50 Mn
Mar 31, 2022 21.39 Mn
Dec 31, 2021 -5.24 Mn
Sep 30, 2021 63.74 Mn